Cancer Research UK Clinical Trials Unit, Birmingham - Adult Unit

Bach, Simon (Co-Investigator)
Bowden, Sarah (Co-Investigator)
Craddock, Charles (Co-Investigator)
Rea, Daniel (Co-Investigator)
Kearns, Pamela (Principal Investigator)
Wheatley, Keith (Co-Investigator)
Billingham, Lucinda (Co-Investigator)
Steven, Neil (Co-Investigator)

Short title	Cancer Research UK Clinical Trials Unit, Birmingham - Adult Unit
Status	Active
Effective start/end date	1/10/18 → 30/09/28

Funding

Cancer Research UK

Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial
Vormoor, B., Savage, J., Kristunas, C., Johnson, S., Blanco, M. N. F., Shenton, G., Lancaster, D., Castleton, A., Fielding, A. K., Latif, A.-L., Morley, N., Strullu, M., Tuckuviene, R., Kearns, P., Jennings, C., Barnett, S., Veal, G. J., Irving, J., Billingham, L. & Menne, T. & 1 others, Vormoor, J., Jun 2026, In: EJC Paediatric Oncology. 7, 10 p., 100489.
Research output: Contribution to journal › Article › peer-review

Open Access
File
17 Downloads (Pure)
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
Middleton, G., Robbins, H. L., Fletcher, P., Savage, J., Mehmi, M., Summers, Y., Greystoke, A., Steele, N., Popat, S., Jain, P., Spicer, J., Cave, J., Shaw, P., Gilligan, D., Power, D., Fennell, D., Bajracharya, M., Mcbride, D. J., Maheswari, U. & Frankell, A. M. & 3 others, Swanton, C., Beggs, A. D. & Billingham, L., 11 Mar 2025, In: npj Precision Oncology. 9, 1, 11 p., 67.
Research output: Contribution to journal › Article › peer-review

Open Access
File
89 Downloads (Pure)
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1
Middleton, G., Gaskell, C., Savage, J., Bridgewater, J., Ross, P., Saunders, M., Palmer, D., Plummer, R., Clive, S., Coyle, V., Thomas, A., Cunningham, D., Taniere, P. & Billingham, L., 17 Dec 2025, In: Journal for ImmunoTherapy of Cancer. 13, 12, 13 p., e012749.
Research output: Contribution to journal › Article › peer-review

Open Access
File
4 Downloads (Pure)

Cancer Research UK Clinical Trials Unit, Birmingham - Adult Unit

Project Details

Funding

Fingerprint

Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer

Cancer Research UK Clinical Trials Unit, Birmingham - Adult Unit

Project Details

Funding

Fingerprint

Research output

Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer